Business opportunities within oncology drug development
הזדמנות עסקית זאת היא בת למעלה מחצי שנה
מומלץ לבדוק האם היא עדיין בתוקף
We are a public traded biotechnology company (NASDAQ OMX:MPI) that has developed a proprietary, highly-validated biomarker selection and patient stratification Dx platform called the Drug Response Predictor (DRP). The transcriptomics-based DRP platform consists of gene expression profiles developed on a system biological interpretation of in vitro data of the drug in question. It has been extensively clinically validated and can substantially predict the indication that will later be approved by the FDA. Our drug development arm - Oncology Venture - (OV) has an exclusive global license to use the DRP-technology to clinically develop anti- cancer drugs. OV's target is to find products that fight to get approval, in-license and invest into these, and perform focused phase 2 trials on highly selected populations that test sensitive for the proprietary biomarker. MPI has offices and laboratories in Denmark (H0rsholm, Copenhagen) and in US (Arizona). Why are we participating in Biomed 2015: We see Israel as a very interesting market and hope to create new business opportunities within oncology drug development. What are we looking for: We would like to contact pharma, or other relevant companies, in order to perform focussed clinical trials and accelerate compounds in their oncology pipeline. Through our Oncology Venture affiliate, we are looking for phase II products, that has shown some but not sufficient efficacy.